GFM
DYN icon

GF Fund Management’s Dyne Therapeutics DYN Stock Holding History

GF Fund Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.4K Buy
3,485
+277
+9% +$5.15K ﹤0.01% 355
2026
Q1 		$58.2K Buy
3,208
+402
+14% +$6.93K ﹤0.01% 380
2025
Q4 		$54.9K Sell
2,806
-255
-8% -$4.83K ﹤0.01% 400
2025
Q3 		$38.7K Buy
3,061
+456
+18% +$5.2K ﹤0.01% 420
2025
Q2 		$24.8K Hold
2,605
– – ﹤0.01% 479
2025
Q1 		$27.2K Buy
2,605
+468
+22% +$6.7K ﹤0.01% 470
2024
Q4 		$50.3K Buy
+2,137
New +$63.2K ﹤0.01% 388

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

GF Fund Management's DYN Position: Q2 2026 in Review

GF Fund Management increased its Dyne Therapeutics (DYN) stake by 8.6% in Q2 2026, buying an estimated $5.15K and bringing the position to 3,485 shares worth $77.4K. The position accounts for ﹤0.01% of the portfolio, ranked #355.

GF Fund Management first reported a position in DYN in Q4 2024 and has held it in 7 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • GF Fund Management held 3,485 shares of Dyne Therapeutics worth $77.4K as of Q2 2026.
  • GF Fund Management bought 277 Dyne Therapeutics shares in Q2 2026, an estimated $5.15K.
  • Dyne Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #355 holding.
  • GF Fund Management first reported a position in Dyne Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.